Q3 FY2026
Filed Nov 5, 2026NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
The company reported a lower quarterly net loss, lower total operating expenses and a higher cash balance following its registered direct offering, alongside positive topline NEO100 Phase 2a results. However, it remains a clinical-stage company with no revenue reported, continuing operating cash use, investigational programs, and a stated requirement for substantial additional capital.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Cash and cash equivalents as of September 30, 2026GAAP | approximately $6.2 million | – | – |
| General and administrative expenses, Q3 2026GAAP | $600K | – | – |
| Research and development expenses, Q3 2026GAAP | $1.3M | – | – |
| Total operating expenses, Q3 2026GAAP | $5.8M | – | – |
| GAAP total operating expenses, three months ended September 30, 2026GAAP | $5,834,350 | – | – |
| Non-cash stock-based compensation expense, three months ended September 30, 2026GAAP | $267,565 | – | – |
| Non-GAAP total operating expenses excluding stock-based compensation, three months ended September 30, 2026non-GAAP | $5,566,785 | – | – |
| Net loss, Q3 2026GAAP | $4.4M | – | 49% decrease |
| Net loss attributable to common stockholders, Q3 2026GAAP | $7.3M | – | – |
| Net loss attributable to common stockholders per basic and diluted share, Q3 2026GAAP | $(0.28) per basic and diluted share | – | – |
| Net loss, nine months ended September 30, 2026GAAP | $27.5M | – | – |
| Net cash used in operating activities, nine months ended September 30, 2026GAAP | $16.8M | – | – |
| Stock-based compensation, nine months ended September 30, 2026GAAP | $8,651,875 | – | – |
Capital returns
- In September, the Company redeemed all 6,000 outstanding shares of its Series A Convertible Preferred Stock for approximately $5.8 million in cash, a discount to the aggregate stated value of $6.0 million.
- No shares of common stock were issued in the redemption, eliminating the potential dilution associated with the preferred stock.
- Mr. Heshmatpour and Dr. Chen purchased a combined 160,016 shares of NeOnc common stock for approximately $629,000 in open-market transactions using personal funds.
What drove it
- The Company closed a registered direct offering on September 10, 2026, for gross proceeds of approximately $15 million, before deducting placement agent fees and other offering expenses.
- General and administrative expenses decreased due to the reversal of previously accrued compensation, lower business development costs and lower travel expenses, partially offset by continued advertising, marketing and investor relations costs.
- Research and development expenses increased with clinical trial site additions, drug-product manufacturing, the NEO100-03 pediatric trial, patient recruitment, NEO100 Phase 2a data-lock and analysis activities, and NEO212 Phase 2a trial design, partially offset by the reversal of previously accrued laboratory fees.
- The Q3 net-loss decrease was driven primarily by lower non-cash stock-based compensation expense, lower operating expenses, lower interest expense on convertible promissory notes repaid in January 2026, and a noncash gain on the change in fair value of the Series A derivative liability.
- The NEO100 Phase 2a study met its primary endpoint, reporting six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047).
Concerns
- The Company reported no revenue, gross margin, operating income or segment revenue.
- The Company stated that it will require substantial additional capital to fund its operations, which may not be available on acceptable terms or at all.
- NEO100 and NEO212 are investigational and have not been approved by any regulatory authority.
- The NEO100 Phase 2a study was a single-arm, open-label study that was not powered as a confirmatory trial.
- The memorandum of understanding with the Department of Health – Abu Dhabi is not binding, and any clinical collaboration or regional activities remain subject to separate agreements and approvals.
What to watch
- Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data are scheduled for presentation on Friday, November 13, 2026, at the Society for Neuro-Oncology Annual Meeting.
- NEO212 is advancing toward Phase 2 development following FDA written feedback on chemistry, manufacturing and controls and the planned transition from a capsule to a tablet formulation.
- Progress of the NEO100-03 pediatric trial and further clinical execution activities.
- Cash usage, access to the undrawn related-party line of credit, and potential use of the at-the-market offering program.
Balance sheet and cash flow
- Cash and cash equivalents were approximately $6.2 million as of September 30, 2026, compared with approximately $2.0 million as of June 30, 2026.
- The increase in cash primarily reflects net proceeds of approximately $13.9 million from the September registered direct offering, partially offset by the approximately $5.8 million cash redemption of the Series A Convertible Preferred Stock and cash used in operations.
- The Company maintained an undrawn $10.0 million line of credit with HCWG, a related party, subject to the terms of the facility.
- Approximately $73.8 million remained available under its at-the-market offering program with BTIG, LLC and A.G.P./Alliance Global Partners.
- Net cash used in operating activities was $16.8 million for the nine months ended September 30, 2026, and 2025.
Analysis
NeOnc reported Q3 2026 net loss of $4.4 million, compared with $8.6 million in Q3 2025, with the release citing lower non-cash stock-based compensation expense, lower operating expenses, lower interest expense on convertible promissory notes repaid in January 2026, and a noncash gain on the change in fair value of the Series A derivative liability. Net loss attributable to common stockholders was $7.3 million, or $(0.28) per basic and diluted share, and included $2.8 million of noncash deemed dividends related to the preferred-stock redemption and a down-round adjustment of previously issued warrants.
Operating expenses were $5.8 million, compared with $6.9 million in Q3 2025. General and administrative expenses declined to $0.6 million from $0.9 million, while research and development expenses rose to $1.3 million from $0.7 million as the company funded clinical execution, manufacturing, the NEO100-03 pediatric trial, recruitment, NEO100 Phase 2a analysis and NEO212 Phase 2a design. The reconciliation reported GAAP total operating expenses of $5,834,350 and non-GAAP total operating expenses excluding stock-based compensation of $5,566,785.
Liquidity improved after the September financing. Cash and cash equivalents were approximately $6.2 million at September 30, 2026, compared with approximately $2.0 million at June 30, 2026. The company cited approximately $13.9 million of net offering proceeds, partly offset by the approximately $5.8 million preferred-stock cash redemption and operating cash use. It also reported an undrawn $10.0 million related-party credit line and approximately $73.8 million of remaining at-the-market capacity. Net cash used in operating activities was $16.8 million for both the nine months ended September 30, 2026 and 2025.
Clinical progress centered on NEO100, for which the Phase 2a study met its primary endpoint with six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047). The company also reported median overall survival of 26.09 months and overall survival rates of 60.9% at 12 months and 54.1% at 24 months. NEO212 continued toward Phase 2 development after FDA written feedback on its CMC program and planned tablet formulation. The near-term focus is the November 13 presentation of updated NEO100 and NEO212 data, while capital needs, ongoing cash use and the investigational status of both programs remain central considerations.
Management, verbatim
The third quarter marked a period of meaningful progress for NeOnc, strengthening our clinical programs, our balance sheet and our international presence.
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer
In September, we raised $15 million from new and existing healthcare-focused institutional investors and used a portion of the proceeds to redeem all of our Series A Convertible Preferred Stock in cash, eliminating its potential dilution for our shareholders.
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer
Not in the filing
stated, not guessed- Revenue was not reported.
- Revenue prior-year comparison and revenue growth were not reported.
- Segment revenue, segment revenue comparisons and segment drivers were not reported.
- Gross profit and gross margin were not reported.
- Operating income or loss was not reported.
- Income tax expense or benefit and tax rate were not reported.
- Quarterly operating cash flow and free cash flow were not reported.
- Debt balance was not reported.
- Share repurchases and dividends were not reported.
- Forward financial guidance was not provided.
- Prior outlook was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.